Examination of end-point tumor burden in Dox-treated or -untreated groups (n = 5 per group) demonstrated that depletion of RBX1 led to profound decreases in tumor weight (68.5% reduction, p < 0.001, Fig. 4b) of the 17ploss tumors, and correspondingly, these tumors had a marked reduction in cell proliferation (as measured by Ki-67 levels) and a significant increase in cell apoptosis (as measured by cleaved caspase-3 levels) (Fig. 4c and Supplementary Fig. 3a). This evidence concerns the gene RBX1 and neoplasm.